Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
48.87
-1.06 (-2.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
35
36
Next >
Is This News a Setback or a Step Forward for CRISPR Therapeutics?
↗
December 06, 2023
It's important to look at the news through a long-term lens.
Via
The Motley Fool
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
↗
December 06, 2023
Via
Benzinga
The Latest Analyst Ratings for CRISPR Therapeutics
↗
December 05, 2023
Via
Benzinga
CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases
↗
December 05, 2023
Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T
Via
Benzinga
Better Growth Stock: CRISPR Therapeutics vs. Invitae
↗
December 05, 2023
One of these stocks may be riskier than the other...
Via
The Motley Fool
The Market's Up This Year. Do You Feel Like You Are Winning?
↗
December 04, 2023
We've also got a look at two stocks worth watching and the popular toys for this holiday season.
Via
The Motley Fool
Is CRISPR Therapeutics the Best Gene-Editing Stock?
↗
November 22, 2023
The biotech's first-mover advantage bodes well for its long-term prospects.
Via
The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
↗
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
↗
December 04, 2023
Vertex shares have soared 400% over the past decade.
Via
The Motley Fool
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today
↗
December 04, 2023
CRISPR Therapeutics' shares advanced in the double-digits this year.
Via
The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
↗
December 03, 2023
The one thing these two stocks have in common is tremendous growth prospects.
Via
The Motley Fool
An Important History Lesson for Gene-Editing Investors
↗
December 02, 2023
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.
Via
The Motley Fool
5 Top Stocks to Buy Before 2024
↗
December 02, 2023
These stocks have room to run -- next year and over the long term.
Via
The Motley Fool
Five Best Performing Stocks Of The Top ETF Of November
↗
December 01, 2023
Most stocks in ARKK’s portfolio delivered strong returns in November. These five led the way.
Via
Talk Markets
Topics
ETFs
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
↗
December 01, 2023
It's not as long a shot as some might think.
Via
The Motley Fool
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
↗
December 01, 2023
These stocks offer enormous long-term growth potential.
Via
The Motley Fool
3 Biotech Stocks That Could Be Multibaggers in the Making
↗
November 30, 2023
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.
Via
InvestorPlace
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
↗
November 29, 2023
The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014.
Via
Benzinga
Topics
ETFs
Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback'
↗
November 29, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here.
Via
Benzinga
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
↗
November 28, 2023
Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies.
Via
InvestorPlace
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
↗
November 28, 2023
These stocks may take off in a market favoring growth.
Via
The Motley Fool
Investing in These 3 Stocks Now Could Make You a Millionaire Retiree
↗
November 25, 2023
These innovators should have tremendous long-term growth prospects.
Via
The Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
↗
November 22, 2023
Many biotech stocks offer exciting long-term growth prospects.
Via
The Motley Fool
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
↗
November 20, 2023
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.
Via
Talk Markets
Topics
ETFs
What's Going On With Crispr Therapeutics Stock Monday?
↗
November 20, 2023
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday on what appears to be continued momentum from the recent regulatory authorization of the company's
Via
Benzinga
Google’s Bard AI Says These 3 Stocks Will Rise 1,000%
↗
November 20, 2023
Google's Bard has been among the best stock pickers, and thinks these three stocks have quadruple-digit upside potential.
Via
InvestorPlace
Topics
Artificial Intelligence
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
↗
November 20, 2023
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?
Via
The Motley Fool
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
↗
November 19, 2023
The stock is trading below its peak, reached a couple of years ago.
Via
The Motley Fool
3 Monster Stocks in the Making
↗
November 18, 2023
These stocks could grow much larger over the next few years.
Via
The Motley Fool
Why CRISPR Therapeutics Stock Is Jumping Again Today
↗
November 17, 2023
The stock continues to enjoy momentum from a key regulatory approval.
Via
The Motley Fool
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
